Valuation: Femasys Inc.

Market Cap 11.2M 9.84M 9.15M 8.4M 15.78M 1.08B 16.02M 109M 42.45M 530M 42.05M 41.15M 1.83B P/E 2026 *
-0.82x
P/E 2027 * -0.68x
Enterprise Value 11.2M 9.84M 9.15M 8.4M 15.78M 1.08B 16.02M 109M 42.45M 530M 42.05M 41.15M 1.83B EV / Sales 2026 *
2.97x
EV / Sales 2027 * 1.12x
Free-Float
90.43%
Yield 2026 *
-
Yield 2027 * -
1 day-2.11%
1 week+23.26%
Current month-11.24%
1 month-2.37%
3 months-54.42%
6 months-69.08%
Current year-67.81%
1 week 3.12
Extreme 3.12
4.22
1 month 2.9
Extreme 2.895
4.78
Current year 2.9
Extreme 2.895
14.51
1 year 2.9
Extreme 2.895
22.2
3 years 2.9
Extreme 2.895
95
5 years 2.9
Extreme 2.895
167.99
10 years 2.9
Extreme 2.895
275
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2004
Director of Finance/CFO 58 28/02/2022
Chief Operating Officer 52 30/03/2026
Director TitleAgeSince
Chairman 58 01/01/2004
Chairman 74 06/07/2022
Director/Board Member 75 01/08/2005
Date Insider Type Main position Quantity % Market Cap.
3/30/26 A Free

Chief Operating Officer

150,000 0.2521%
3/30/26 A Other

Chief Operating Officer

30,000 0.0504%
3/19/26 A Free

Director

102,366 0.1720%
Change 5-day change 1-year change 3-year change Capi.($)
-2.11%+23.26%-79.39%-49.04% 11.2M
+2.29%+2.36%-18.56%-9.66% 180B
+1.46%+0.01%-10.47%-7.95% 107B
+1.58%+0.65%+6.73%+65.09% 60.29B
+0.73%-3.08%+26.45%+55.17% 50.19B
+2.22%-1.14%-15.63%-44.71% 43.08B
+2.98%-2.61% - - 32.77B
+1.50%-6.67%-19.61%-45.26% 27.61B
-7.67%-8.39%+24.55%-13.50% 23.1B
+1.63%-1.73%-7.11%-7.67% 20.86B
Average +0.43%+0.31%-10.34%-6.39% 54.39B
Weighted average by Cap. +1.42%-0.40%-6.87%+0.91%

Financials

2026 *2027 *
Net sales 3.77M 3.31M 3.08M 2.82M 5.3M 363M 5.39M 36.53M 14.27M 178M 14.14M 13.83M 617M 10M 8.78M 8.17M 7.5M 14.09M 963M 14.3M 97.01M 37.9M 474M 37.55M 36.74M 1.64B
Net income -16.22M -14.25M -13.25M -12.16M -22.84M -1.56B -23.19M -157M -61.46M -768M -60.89M -59.57M -2.65B -21.29M -18.69M -17.39M -15.95M -29.98M -2.05B -30.44M -206M -80.66M -1.01B -79.91M -78.18M -3.48B
Net Debt - -
Logo Femasys Inc.
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Employees
53
Date Price Change Volume
24/07/26 $3.710 -2.11% 35,266
23/07/26 $3.790 +7.67% 20,961
22/07/26 $3.520 -9.97% 123,455
21/07/26 $3.910 +19.57% 226,220
20/07/26 $3.270 +8.64% 14,579
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.710USD
Average target price
63.33USD
Spread / Average Target
+1,607.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FEMY Stock